Massachusetts Unveils Opioid Settlement Dashboard as Municipalities Sit on $95 Million

Massachusetts health officials launched a public transparency dashboard Wednesday tracking how the state and its municipalities spend nearly $1 billion in opioid settlement funds — and the first year's data reveals a troubling pattern: local governments are stockpiling cash while addiction services remain underfunded.

The Department of Public Health's Statewide Opioid Settlement Funds Dashboard shows municipalities reported having $107.7 million available in the fiscal year ending June 2025, yet spent only $13.2 million — a mere 12 percent. The remaining $94.5 million sits in municipal accounts as communities continue assessing needs, engaging stakeholders, and identifying investment strategies.

"The launch of this dashboard is about more than simply providing data — it reflects the department's ongoing commitment to transparency, accountability and fostering public trust," Public Health Commissioner Dr. Robbie Goldstein said in announcing the system.

Transparency Through Technology

The new dashboard consolidates information previously scattered across separate state and municipal reporting systems. It breaks down settlement revenues and expenditures by fiscal year, providing real-time visibility into how Massachusetts allocates funds for substance use prevention, harm reduction, addiction treatment, and recovery programs.

State officials pledged annual updates to the platform, which absorbs a prior municipal-focused dashboard into a unified statewide view. The tool represents one of the most comprehensive public accountability systems for opioid settlement spending nationwide, coming as states face growing pressure to demonstrate responsible stewardship of pharmaceutical lawsuit proceeds.

The $1 billion Massachusetts expects to receive between 2021 and 2039 stems from settlements in lawsuits against pharmaceutical companies, distributors, and retailers over their role in the opioid crisis. Plaintiffs alleged the companies aggressively marketed highly addictive pain medications, fueling an epidemic that has killed tens of thousands of Americans annually through overdoses.

60-40 Split Creates Two Tracks

Settlement funds flow through two channels under Massachusetts' allocation structure: 60 percent goes to the state's Opioid Recovery and Remediation Fund, while municipalities receive the remaining 40 percent through Municipal Opioid Abatement Funds.

The state fund has received $219 million in total opioid settlement proceeds to date. Last fiscal year, the state collected $40 million in new settlement payments and, combined with funds carried over from prior years, spent $61 million on opioid response programs.

A significant portion of state spending went to the Mosaic Opioid Recovery Partnership, which awarded $13 million in grants to municipalities and community organizations for substance use prevention, harm reduction, treatment, and recovery programs. Recent grant cycles prioritized programs serving children and families affected by the overdose crisis.

Municipal spending tells a different story. While local governments collectively held more than $100 million in available funds during FY2025, their $13.2 million in expenditures suggests either cautious planning or bureaucratic paralysis.

State officials attribute the low municipal spending rate to ongoing needs assessments and community engagement processes. Many cities and towns are consulting residents affected by the opioid crisis before committing funds to specific interventions — a deliberative approach that contrasts with the urgency advocates say the crisis demands.

Physician-Led Leadership

Secretary of Health and Human Services Dr. Kiame Mahaniah, who specialized in addiction medicine and primary care before joining state government, framed the dashboard as a tool for fostering public participation in settlement fund governance.

"This tool allows for greater public awareness and input to continue informing decisions around how these critical resources are being put to use," Mahaniah said.

Both Mahaniah and Goldstein bring clinical backgrounds to their roles, lending medical credibility to the state's public health approach to opioid settlement stewardship. Their emphasis on transparency reflects broader concerns about accountability in settlement spending, particularly after investigative reporting in states like Mississippi exposed conflicts of interest and questionable allocation decisions.

National Context: The Accountability Movement

Massachusetts joins a growing number of states implementing transparency measures for opioid settlement funds. Maine recently published its first annual spending report under a new state law requiring detailed public disclosure. Mississippi's legislature passed sweeping reforms in March 2026 following an investigation that revealed council members approving grants to their own organizations.

The Massachusetts dashboard arrives as settlement dollars continue flowing from multi-billion-dollar agreements with pharmaceutical manufacturers and distributors. Purdue Pharma, Johnson & Johnson, Cardinal Health, McKesson, and AmerisourceBergen have collectively paid tens of billions in settlements, with funds distributed to states and localities based on formulas accounting for overdose death rates, treatment needs, and population.

Legal experts note that while settlements require funds be used for opioid abatement, specific spending decisions rest with state and local governments. This decentralized structure creates variation in how communities prioritize prevention, treatment, harm reduction, or recovery services.

Evidence-Based Spending vs. Local Autonomy

Massachusetts' dual-track funding structure balances state-level coordination with municipal autonomy. The Opioid Recovery and Remediation Fund operates through a formal advisory council that reviews proposals and recommends allocations to the Department of Public Health. Municipal funds, by contrast, allow local decision-makers to tailor interventions to community-specific needs.

The tension between evidence-based best practices and local control surfaces repeatedly in settlement spending debates. Public health researchers advocate for investments proven effective in clinical trials: medication-assisted treatment, naloxone distribution, syringe service programs, and housing-linked recovery support. Community leaders sometimes prioritize different interventions — prevention education, law enforcement partnerships, or criminal justice diversion programs — that resonate with local values but may lack comparable research backing.

Massachusetts' transparency dashboard doesn't prescribe spending priorities, but its public nature creates reputational pressure. Municipalities with large unspent balances may face constituent questions about delays, while jurisdictions demonstrating rapid deployment of evidence-based programs could emerge as models.

What the Data Reveals

The FY2025 figures show the state fund's $61 million in expenditures included not only the $13 million in Mosaic grants but also investments in treatment infrastructure, harm reduction supplies, workforce development, and data systems. Specific allocations remain partially obscured in summary figures, though future dashboard updates promise more granular breakdowns.

Municipal spending patterns vary widely. Some communities allocated funds to behavioral health liaisons embedded in police departments, while others invested in recovery community centers, jail-based medication-assisted treatment programs, or youth prevention initiatives. The dashboard's municipality-level data will reveal which approaches cities and towns are prioritizing.

Early indications suggest many municipalities are banking settlement funds for multi-year projects rather than one-time expenditures. A regional detox facility, for instance, might require several years of accumulated settlement revenues to finance construction and staffing.

But addiction recovery advocates warn that excessive caution becomes complicity when people continue dying from preventable overdoses. Massachusetts recorded approximately 2,200 opioid-related deaths in 2024, down from pandemic peaks but still far above pre-2015 levels.

The Dashboard's Impact

Public transparency tools like Massachusetts' dashboard serve multiple functions beyond accountability. They educate policymakers about what peer jurisdictions are funding, creating opportunities for evidence-sharing and best practice dissemination. They empower advocacy groups with data to press for specific investments. And they give researchers longitudinal data sets tracking which interventions correlate with improved outcomes.

The dashboard's annual update cycle creates a natural accountability rhythm. Municipalities sitting on large unspent balances for multiple consecutive years will face mounting pressure to either allocate funds or explain delays. State legislators may use dashboard data to inform future opioid policy legislation, adjusting funding formulas or adding accountability requirements if spending remains sluggish.

Massachusetts' approach also provides a template for other states grappling with settlement transparency. As billions in opioid settlement dollars continue flowing through state coffers over the next 13 years, the demand for public accountability will only intensify.

Looking Ahead

The dashboard's launch comes at an inflection point for addiction policy. The opioid crisis that settlements ostensibly address has evolved beyond prescription painkillers into a polysubstance epidemic involving fentanyl, methamphetamine, and xylazine. Settlement funds originally conceived to address opioid addiction now face pressure to respond to broader substance use challenges.

Massachusetts officials have signaled openness to flexible interpretations of allowable expenditures, permitting settlement funds to address co-occurring substance use disorders and mental health conditions that intersect with opioid addiction. This pragmatic approach acknowledges clinical reality: most people seeking opioid treatment also use other substances or struggle with psychiatric conditions.

The state's physician leadership — both Goldstein and Mahaniah bring clinical training to their roles — positions Massachusetts to ground settlement spending in medical evidence rather than political expediency. Their emphasis on children and families affected by addiction suggests priorities beyond traditional treatment silos.

But transparency without action means little. The dashboard's real test will come in next year's data release, when municipalities either demonstrate meaningful deployment of funds or continue hoarding resources while the crisis persists.

For now, the tool exists. The public has access. The question is whether sunlight will prove the disinfectant advocates hope for — or whether bureaucratic inertia will outlast public attention spans.